Treatment in parent studies | Entry route into maintenance phase | Patients in remission at the end of 12 months, n (%) | ||
MMX mesalazine 2.4 g/day | Total | |||
2.4 g given once daily (n = 225) | 1.2 g given twice daily (n = 234) | |||
Placebo | Direct | 18/22 (81.8) | 16/20 (80.0) | 34/42 (81.0) |
Via 8-week extension | 19/34 (55.9) | 25/41 (61.0) | 44/75 (58.7) | |
MMX mesalazine 2.4 g/day* | Direct | 25/37 (67.6) | 33/42 (78.6) | 58/79 (73.4) |
Via 8-week extension | 14/29 (48.3) | 13/24 (54.2) | 27/53 (50.9) | |
MMX mesalamine 4.8 g/day | Direct | 30/42 (71.4) | 32/41 (78.0) | 62/83 (74.7) |
Via 8-week extension | 15/27 (55.6) | 17/28 (60.7) | 32/55 (58.2) | |
Asacol 2.4 g/day† | Direct | 15/17 (88.2) | 13/19 (68.4) | 28/36 (77.8) |
Via 8-week extension | 5/11 (45.5) | 10/17 (58.8) | 15/28 (53.6) |
*Patients received MMX mesalazine 2.4 g/day given once daily in the Kamm study,25 and as 1.2 g twice daily in the Lichtenstein study.24 †Patients received Asacol 2.4 g/day (given as 0.8 g three times daily) as a reference arm in study 302 only.